Home > Focus on Glioblastoma Treatment and Bevacizumab – Dr. Annick Desjardins ASCO 2014
Neurological Oncology

Focus on Glioblastoma Treatment and Bevacizumab – Dr. Annick Desjardins ASCO 2014

Published Online: August 24th 2014

From ASCO 2014, Dr. Annick Desjardins of Duke University discusses the retrospective focus on glioblastoma treatment and the use of bevacizumab.

Share this Video
Related Videos In Neurological Oncology
Neurological Oncology
Soffietti_T2.png
Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 2)

Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 2 of 2. Questions 1. What are the most promising agents targeting […]

Neurological Oncology
Soffietti_T1.png
Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 1)

Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 1 of 2. Questions 1 What have been the most important recent […]

Neurological Oncology
Soffietti_T.png
EAN 2017 – Riccardo Soffietti Interview – Part 3

EAN Programme Committee Member, Prof. Riccardo Soffietti, provides his insights on neuro-oncology coverage at this year’s EAN congress. Part 3 of 3. View Part 1 here. View Part 2 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June […]

Trending In Neurological Oncology:

Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 2)
Neurological Oncology
    • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72